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Abstract: Background: T cell density in colorectal cancer (CRC) has proven to be of high prognostic 
importance. Here, we evaluated the influence of a hyperfractionated preoperative short-term 
radiation protocol (25 Gy) on immune cell density in tumor samples of rectal cancer (RC) patients 
and on patient survival. In addition, we assessed spatial tumor heterogeneity by comparison of 
analogue T cell quantification on full tissue sections with digital T cell quantification on a virtually 
established tissue microarray (TMA). Methods: A total of 75 RC patients (60 irradiated, 15 treatment-
naïve) were defined for retrospective analysis. RC samples were processed for 
immunohistochemistry (CD3, CD8, PD-1, PD-L1). Analogue (score 0–3) as well as digital 
quantification (TMA: 2 cores vs. 6 cores, mean T cell count) of marker expression in 2 areas (central 
tumor, CT; invasive margin, IM) was performed. Survival was estimated on the basis of analogue 
as well as digital marker densities calculated from 2 cores (Immunoscore: CD3/CD8 ratio) and 6 
cores per tumor area. Results: Irradiated RC samples showed a significant decrease in CD3 and CD8 
positive T cells, independent of quantification mode. T cell densities of 6 virtual cores approximated 
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to T cell densities of full tissue sections, independent of individual core density or location. Survival 
analysis based on full tissue section quantification demonstrated that CD3 and CD8 positive T cells 
as well as PD-1 positive tumor infiltrating leucocytes (TILs) in the CT and the IM had a significant 
impact on disease-free survival (DFS) as well as overall survival (OS). In addition, CD3 and CD8 
positive T cells as well as PD-1 positive TILs in the IM proved as independent prognostic factors for 
DFS and OS; in the CT, PD-1 positive TILs predicted DFS and CD3 and CD8 positive T cells as well 
as PD-1 positive TILs predicted OS. Survival analysis based on virtual TMA showed no impact on 
DFS or OS. Conclusion: Spatial tumor heterogeneity might result in inadequate quantification of 
immune marker expression; however, if using a TMA, 6 cores per tumor area and patient sample 
represent comparable amounts of T cell densities to those quantified on full tissue sections. 
Consistently, the tissue area used for immune marker quantification represents a crucial factor for 
the evaluation of prognostic and predictive biomarker potential. 




A balanced tumor microenvironment can ignite tumor immune surveillance to promote local 
and distant tumor control [1–7]. The Immunoscore, that is based on the tumor immune contexture, 
has recently been validated as a prognostic factor for survival of colorectal cancer (CRC) patients [8]. 
The clinical implementation of immune checkpoint blockade has emerged as one of the greatest 
advantages in cancer immunotherapy and can lead to long-term regression [9,10]. An “immune-
high” tumor microenvironment and the consecutive activation of the immune checkpoint axis is 
ascribed to CRCs with a high mutational load (15% microsatellite unstable tumors) [11,12]. 
Accordingly, immune checkpoint blockade is associated with improved survival in this subgroup of 
patients; however, the majority of patients present with ”immune-low” tumors that are not 
responsive to immune checkpoint blockade [13]. 
Irradiation can ignite pro-immunogenic effects, that depend on dose, fractionation and 
sequencing [14]. If appropriately applied, it might shape a tumor microenvironment potentially 
responsive to immune checkpoint blockade. However, data on synergistic effects of irradiation and 
immunotherapy are inconsistent, since irradiation protocols that have been investigated were chosen 
empirically rather than rationally [15]. In rectal cancer (RC) specimens, preoperative 
radiochemotherapy resulted in the significant infiltration of CD8 positive T cells whereas the 
expression of immune checkpoint receptors remained stable [16]. Good histopathological response 
to preoperative treatment was associated with CD3 and CD8 positive T cell densities [16–18]. In a 
murine CRC model, ablative irradiation led to an increase in CD8 positive lymphocytes in the tumor 
microenvironment, whereas fractionated irradiation showed lower levels of lymphocyte infiltration 
[19]. However, recent reports have investigated different preoperative treatment protocols that 
demonstrate heterogeneous data on tumor immune cell infiltration quantified with different methods 
(biopsies, tissue microarray (TMA), full tissue sections). 
Recently, several issues have been raised concerning the method of immune marker 
quantification employed. Spatial tumor heterogeneity of target molecules in cancer tissue is well 
described [20–26]; however, histologic sampling by TMA is still regularly used for marker analysis 
[18,27,28], although it involves the risk of underestimation [22,24,28]. The Immunoscore uses two 
cores in two tumor areas each (CT, IM) for quantification of immune cell densities in CRC [18,27]. 
Interestingly, heterogeneity of tumor infiltrating immune cell densities in primary CRCs compared 
to intralesional homogeneity of infiltrating immune cells in hepatic metastases has been confirmed 
in a recent study by Halama et al.; here, the evaluation of single fields for immune cell density in 
hepatic metastases showed that values in up to five fields did not add further approximation to the 
average immune cell value [29]. 
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In this study, we evaluated an immunomodulatory effect of a hyper-fractionated short-term 
radiation protocol in RC patients and the proposed differences in immune marker densities that 
might be caused by the choice of mode of analysis using full tissue sections versus (virtual) TMA; in 
addition, we defined the minimal tissue area needed for quantification. The results of this study 
should contribute to the body of knowledge on irradiation-induced immunogenicity by elucidating 
the immunogenic effects of a clinically employed preoperative radiation protocol [30]; furthermore, 
these data should encourage the optimization of effective and tissue-saving immune cell marker 
quantification. 
2. Results 
2.1. Preoperative Radiation Therapy Is Associated with a Lower Density of Infiltrating T Cells and a Lower 
Dukes Stage with High Levels of PD-L1 Positive Tumor Infiltrating Lymphocytes (TILs) 
Quantification of infiltrating T cells (cells positive for CD3 or CD8 expression) on full tumor 
tissue sections, showed that preoperative radiation therapy was associated with a significant 
reduction in CD8 positive T cell density in the central tumor (CD8: p = 0.017) as well as reduced CD3, 
CD8 density and PD-1 expression level on TILs at the invasive margin (CD3: p = 0.006, CD8: p = 0.001, 
PD-1: p = 0.005). In addition, high PD-L1 expression in the central tumor as well as at the invasive 
margin correlated with a lower Dukes stage (PD-L1: CT: R = –0.23, p = 0.046; IM: R= –0.24, p = 0.041; 
Tables 1–4). Of note, PD-1 and PD-L1 expression were exclusively detected on TILs, but not on tumor 
cells.
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Table 1. Patient and tumor characteristics in relation to the level of CD3 T cell expression determined analogously on full tissue sections. 
 CD3 – central tumor CD3 – invasive margin 
Factor No. of patients (%) 0 1 2 3 0 1 2 3 
 75 (100.0%) 9 (12.0%) 34 (45.7%) 19 (25.3%) 13 (17.3%) 8 (10.7%) 28 (37.3%) 28 (37.3%) 1 (14.7%) 
Median age (range) 77 (51–94) n.s.* n.s.* 
Sex n.s.** n.s.** 
female 31 (41.3%) 3 (4.0%) 16 (21.3%) 7 (9.3%) 5 (6.7%) 3 (4.0%) 12 (16.0%) 13 (17.3%) 3 (4.0%) 
male 44 (58.7%) 6 (8.0%) 18 (24.0%) 12 (16.0%) 8 (19.7%) 5 (6.7%) 16 (21.3%) 15 (20.0%) 8 (10.7%) 
Preoperative RTx n.s.** p = 0.006** 
Yes 60 (80.0%) 26 (34.7%) 9 (12.0%) 26 (34.7%) 9 (12.0%) 26 (34.7%) 9 (12.0%) 26 (34.7%) 3 (4.0%) 
No 15 (20.0%) 8 (10.7%) 0 (0.0%) 8 (10.7%) 0 (0.0%) 8 (10.7%) 0 (0.0%) 8 (10.7%) 4 (5.3%) 
Tumor grading (G) n.s.* n.s.* 
Good (G1) 1 (1.3%) 0 (0.0%) 0 (0.0%) 1 (1.3%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (1.3%) 0 (0.0%) 
Moderate (G2) 63 (84.0%) 8 (10.7%) 25 (37.3%) 15 (20.0%) 12 (16.0%) 8 (10.7%) 22 (29.3%) 25 (33.3%) 8 (10.7%) 
Poor (G3) 11 (14.7%) 1 (1.3%) 6 (8.0%) 3 (4.0%) 1 (1.3%) 0 (0.0%) 6 (8.0%) 2 (2.7%) 3 (4.0%) 
Dukes stage n.s.* n.s.* 
Stage A 21 (28.0%) 2 (2.7%) 7 (9.3%) 6 (8.0%) 6 (8.0%) 2 (2.7%) 6 (8.0%) 12 (16.0%) 1 (1.3%) 
Stage B 25 (33.3%) 3 (4.0%) 14 (18.7%) 4 (5.3%) 4 (5.3%) 2 (2.7%) 11 (14.7%) 9 (12.0%) 3 (4.0%) 
Stage C 24 (32.0%) 2 (2.7%) 12 (16.0%) 8 (10.7%) 2 (2.7%) 3 (4.0%) 11 (14.7%) 3 (4.0%) 7 (9.3%) 
Stage D 5 (6.7%) 2 (2.6%) 1 (1.3%) 1 (1.3%) 1 (1.3%) 1 (1.3%) 0 (0.0%) 4 (5.3%) 0 (0.0%) 
Note. RTx: radiation therapy (hyper-fractionated short-term radiation protocol; 2× 2.5 Gy/d during 5d: total dose of 25 Gy); RC: rectal cancer; progressive disease: 
lymph node and/or distant metastases; *Spearman correlation statistical significance, **Approximative Linear-by-Linear Association Test; bold p-values—statistical 
significance at the p < 0.05 level. 
Table 2. Patient and tumor characteristics in relation to the level of CD8 T cell expression determined analogously on full tissue sections. 
 CD8 – central tumor CD8 – invasive margin 
Factor No. of patients (%) 0 1 2 3 0 1 2 3 
 75 (100.0%) 15 (20.0%) 46 (61.3%) 10 (13.3%) 4 (5.3%) 12 (16.0%) 37 (49.3%) 19 (25.3%) 7 (9.3%) 
Median age (range) 77 (51–94) n.s.* n.s.* 
Sex n.s.** n.s.** 
female 31 (41.3%) 7 (9.3%) 19 (25.3%) 3 (4.0%) 2 (2.7%) 4 (5.3%) 17 (22.7%) 7 (9.3%) 3 (4.0%) 
male 44 (58.7%) 8 (10.7%) 27 (36.0%) 7 (9.3%) 2 (2.7%) 8 (10.7%) 20 (26.7%) 12 (16.0%) 4 (5.3%) 
Preoperative RTx p = 0.017** p = 0.001** 
Yes 60 (80.0%) 15 (20.0%) 36 (48.0%) 7 (9.3%) 2 (2.7%) 12 (16.0%) 35 (46.7%) 10 (13.3%) 3 (4.0%) 
No 15 (20.0%) 0 (0.0%) 10 (13.3%) 3 (4.0%) 2 (2.7%) 0 (0.0%) 2 (2.7%) 9 (12.0%) 4 (5.3%) 
Tumor grading (G) n.s.* n.s.* 
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Good (G1) 1 (1.3%) 0 (0.0%) 1 (1.3%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (1.3%) 0 (0.0%) 0 (0.0%) 
Moderate (G2) 63 (84.0%) 13 (17.3%) 37 (49.3%) 10 (13.3%) 3 4.0%) 10 (13.3%) 30 (40.0%) 17 (22.7%) 6 (8.0%) 
Poor (G3) 11 (14.7%) 2 (2.7%) 8 (10.7%) 0 (0.0%) 1 (1.3%) 2 (2.7%) 6 (8.0%) 2 (2.7%) 1 (1.3%) 
Dukes stage n.s.* n.s.* 
Stage A 21 (28.0%) 4 (5.3%) 11 (14.7%) 6 (8.0%) 0 (0.0%) 2 (2.7%) 12 (16.0%) 7 (9.3%) 0 (0.0%) 
Stage B 25 (33.3%) 6 (8.0%) 15 (20.0%) 2 (2.7%) 2 (2.7%) 5 (6.7%) 12 (16.0%) 5 (6.7%) 3 (4.0%) 
Stage C 24 (32.0%) 4 (5.3%) 17 (22.7%) 1 (1.3%) 2 (2.7%) 5 (6.7%) 11 (14.7%) 5 (6.7%) 3 (4.0%) 
Stage D 5 (6.7%) 1 (2.7%) 3 (4.0%) 1 (2.7%) 0 (0.0%) 0 (0.0%) 2 (2.7%) 2 (2.7%) 1 (1.3%) 
Note. RTx: radiation therapy (hyper-fractionated short-term radiation protocol; 2× 2.5 Gy/d during 5d: total dose of 25 Gy); RC: rectal cancer; progressive disease: 
lymph node and/or distant metastases; * Spearman correlation statistical significance, ** Approximative Linear-by-Linear Association Test; bold p-values—statistical 
significance at the p < 0.05 level. 
Table 3. Patient and tumor characteristics in relation to the level of PD-1 immune checkpoint protein expression determined analogously on full tissue sections. 
 PD-1 – central tumor* PD-1 – invasive margin* 
Factor No. of patients (%) 0 1 2 0 1 2 
 75 (100%) 25 (33.3%) 42 (56.0%) 8 (10.7%) 26 (34.7%) 37 (49.3%) 12 (16.0%) 
Median age (range) 77 (51–94) n.s.** n.s.** 
Sex n.s.*** n.s.*** 
female 31 (41.3%) 10 (13.3%) 19 (25.3%) 2 (2.7%) 12 (16.0%) 13 (17.3%) 6 (8.0%) 
male 44 (58.7%) 15 (20.0%) 23 (30.7%) 6 (8.0%) 14 (18.7%) 24 (32.0%) 6 (8.0%) 
Preoperative RTx n.s.*** p = 0.005*** 
Yes 60 (80.0%) 23 (30.7%) 31 (41.3%) 6 (8.0%) 2 (2.7%) 7 (9.3%) 6 (8.0%) 
No 15 (20.0%) 2 (2.7%) 11 (14.6%) 2 (2.7%) 24 (32.0%) 30 (40.0%) 6 (8.0%) 
Tumor grading (G) n.s.** n.s.** 
Good (G1) 1 (1.3%) 0 (0.0%) 1 (1.3%) 0 (0.0%) 0 (0.0%) 1 (1.3%) 0 (0.0%) 
Moderate (G2) 63 (84.0%) 21 (28.0%) 35 (46.7%) 7 (9.3%) 22 (29.3%) 31 (41.3%) 10 (13.3%) 
Poor (G3) 11 (14.7%) 4 (5.3%) 6 (8.0%) 1 (1.3%) 4 (5.3%) 5 (6.7%) 2 (2.7%) 
Dukes stage n.s.** n.s.** 
Stage A 21 (28.0%) 4 (5.3%) 13 (17.4%) 4 (5.3%) 3 (4.0%) 15 (20.0%) 3 (4.0%) 
Stage B 25 (33.3%) 11 (14.7%) 11 (14.6%) 3 (4.0%) 11 (14.6%) 10 (13.3%) 4 (5.3%) 
Stage C 24 (32.0%) 9 (12.0%) 14 (18.7%) 1 (1.3%) 11 (14.6%) 10 (13.3%) 3 (4.0%) 
Stage D 5 (6.7%) 1 (1.3%) 4 (5.3%) 0 (0.0%) 1 (1.3%) 2 (2.7%) 2 (2.7%) 
Note. *PD-1 expression was exclusively found on tumor infiltrating lymphocytes. RTx: radiation therapy (hyper-fractionated short-term radiation protocol; 2× 2.5 
Gy/d during 5d: total dose of 25 Gy); RC: rectal cancer; progressive disease: lymph node and/or distant metastases; **Spearman correlation statistical significance, 
***Approximative Linear-by-Linear Association Test; bold p-values—statistical significance at the p < 0.05 level. 
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Table 4. Patient and tumor characteristics in relation to the level of PD-L1 immune checkpoint protein expression determined analogously on full tissue sections. 
 PD-L1 – central tumor* PD-L1 – invasive margin* 
Factor No. of patients (%) 0 1 2 3 0 1 2 3 
 75 (100.0%) 42 (56.0%) 15 (20.0%) 15 (20.0%) 3 (4.0%) 47 (62.7%) 12 (16.0%) 13 (17.3%) 3 (4.0%) 
Median age (range) 77 (51–94) n.s.** n.s.** 
Sex n.s.*** n.s.*** 
female 31 (41.3%) 16 (21.3%) 7 (9.3%) 6 (8.0%) 2 (2.7%) 20 (26.7%) 4 (5.3%) 6 (8.0%) 1 (1.3%) 
male 44 (58.7%) 26 (34.7%) 8 (10.7%) 9 (12.0%) 1 (1.3%) 27 (36%) 8 (10.7%) 7 (9.3%) 2 (2.7%) 
Preoperative RTx n.s.*** n.s.*** 
Yes 60 (80.0%) 36 (48.0%) 10 (13.3%) 11 (14.7%) 3 (4.0%) 40 (53.3%) 9 (12.0%) 8 (10.7%) 3 (4.0%) 
No 15 (20.0%) 6 (8.0%) 5 (6.7%) 4 (5.3%) 0 (0.0%) 7 (9.3%) 3 (4.0%) 5 (6.7%) 0 (0.0%) 
Tumor grading (G) n.s.** n.s.** 
Good (G1) 1 (1.3%) 0 (0.0%) 0 (0.0%) 1 (1.3%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (1.33%) 0 (0.0%) 
Moderate (G2) 63 (84.0%) 36 (48.0%) 14 (18.7%) 10 (13.3%) 3 (4.0%) 39 (52.0%) 11 (14.7%) 10 (13.3%) 3 (4.0%) 
Poor (G3) 11 (14.7%) 6 (8.0%) 1 (1.33%) 4 (5.3%) 0 (0.0%) 8 (10.7%) 1 (1.3%) 2 (3.7%) 0 (0.0%) 
Dukes stage R = −0.23, p = 0.046** R = −0.24, p = 0.041** 
Stage A 21 (28.0%) 10 (13.3%) 3 (4.0%) 7 (9.3%) 1 (1.3%) 9 (12.0%) 4 (5.3%) 6 (8.0%) 2 (3.7%) 
Stage B 25 (33.3%) 12 (16.0%) 7 (9.3%) 4 (5.3%) 2 (2.7%) 18 (24.0%) 3 (4.0%) 3 (4.0%) 1 (1.3%) 
Stage C 24 (32.0%) 16 (21.3%) 4 (5.3%) 4 (5.3%) 0 (0.0%) 16 (21.2%) 4 (5.4%) 4 (5.4%) 0 (0.0%) 
Stage D 5 (6.7%) 4 (5.3%) 1 (1.3%) 0 (0.0%) 0 (0.0%) 4 (5.3%) 1 (1.3%) 0 (0.0%) 0 (0.0%) 
Note. *PD-L1 expression was exclusively found on tumor infiltrating lymphocytes. RTx: radiation therapy (hyper-fractionated short-term radiation protocol; 2× 2.5 
Gy/d during 5d: total dose of 25 Gy); RC: rectal cancer; progressive disease: lymph node and/or distant metastases; **Spearman correlation statistical significance, 
***Approximative Linear-by-Linear Association Test, bold p-values—statistical significance at the p < 0.05 level.
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2.2. A Decrease in T Cell Density Is Observed Only at the Invasive Margin of Tumors That Have Been 
Exposed to Radiation Therapy 
To validate these exploratory findings, the full patient cohort (60 irradiated and 15 treatment-
naïve RC samples) were analyzed following immunohistochemical staining of full tissue sections. T 
cell and immune checkpoint protein expression were compared according to their staining intensity. 
Less CD8 density and a trend towards less CD3 density was observed at the invasive margin of full 
tissue sections (p < 0.0001 and p = 0.0970; Figure 1A); no significant differences were found in CD3 
and CD8 density in the central tumor (p = 1 and p = 0.183, respectively). 
In order to determine whether analysis of sample cores as opposed to full tissue sections 
provides similar results therefore negating the need to analyze full tissue sections, a virtual TMA was 
established using two cores from each tumor area of the scanned full section (Figure 2, left). Analysis 
of irradiated vs. treatment-naïve RC samples applying this methodology showed significantly less 
CD3 and CD8 T cell density in irradiated RC samples at the invasive margin (p < 0.0001 each, Figure 
1B); again, no significant differences were found between CD3 and CD8 density in the central tumor 
(p = 0.864 and p = 0.227, respectively). Similarly, analysis of irradiated vs. treatment-naïve RC samples 
using 6 cores from each tumor area showed significantly less CD3 and CD8 T cell density in irradiated 
RC samples at the invasive margin (p < 0.0001 each, Figure 1C); no significant differences were found 
between CD3 and CD8 density in the central tumor (p = 0.202 and p = 0.424, respectively). These data 
are suggestive of immunosuppression in irradiated RC samples. Of note, analogue quantification of 
T cell density and immune checkpoint protein expression demonstrated a heterogeneous pattern of 
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Figure 1. Correlative analysis of T cell density in preoperatively irradiated vs. treatment-naïve rectal 
cancer specimens quantified by analogue using full tissue sections (A) and on virtually established 
tissue microarray (TMA; (B) 2 cores per tumor region and (C) 6 cores per tumor region). A. 25 Gy of 
preoperative irradiation significantly attenuates marginal density of CD8 positive T cells observed on 
full tissue sections (p < 0.0001); a trend was shown towards less CD3 density in the IM (p = 0.0970). B. 
25 Gy of preoperative irradiation significantly attenuates marginal density of CD3 as well as CD8 
positive T cells seen on virtual TMAs using 2 cores (p < 0.0001 each). C. 25 Gy of preoperative 
irradiation significantly attenuates marginal density of CD3 as well as CD8 T cells seen on virtual 
TMA using 6 cores (p < 0.0001 each). 
 
Figure 2. Virtual TMA establishment on scanned full section slides of rectal cancer (RC) samples using 
StrataQuestTM®. (Left): Randomly selected virtual cores in the central tumor (2x 0.6mm diameter) 
and in the invasive margin (2x 1mm diameter) on full section slides of RC samples. (Right): Expansion 
of virtual core establishment from 2 to a maximum of 6 cores per tumor region taking into account the 
minimum amount of tumor area available amongst all full section slides. Note. Bar graph = 500 µm. 
2.3. T Cell Density Correlates between Quantification Methods 
Due to the improved significance of T cell density in the invasive margin when quantified on a 
virtual TMA (compared to full tissue sections), we expanded the number of virtual cores to a 
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maximum of six per tumor area, Figure 2, right). We then compared full section scores with mean T 
cell densities of the core 1–6. For the most part, T cell density scores on full tissue sections 
corresponded with mean T cell density determined on the virtual TMA. However, results showed 
positive, but variable correlations between quantification methods in each tumor region, with weak 
correlations between CD3 density (tumoral and marginal CD3 positive T cells: R = 0.35 and R = 0.14, 
respectively) and moderate to strong correlations in CD8 density (tumoral and marginal CD8 positive 
T cells: R = 0.45 and R = 0.69, respectively; Figure 3). 
 
Figure 3. Correlative analysis of T cell densities quantified on full tissue sections (score 0–3) vs. mean 
T cell densities of 6 cores. T cell densities of the 2 quantification methods match with respect to 
correlational strength in the different tumor areas. Top: Tumoral and marginal CD3 positive T cells: 
R = 0.35 (medium correlation) and R = 0.14 (weak correlation), respectively. Bottom: Tumoral and 
marginal CD8 positive T cells: R = 0.45 (medium correlation) and R = 0.69 (good correlation), 
respectively. Note. Score: no (0), low (1), moderate (2) or high (3) protein levels with respect to positive 
T cells or TILs present; R—Spearman's correlation coefficient. 
2.4. Determination of T Cell Density Varies According to the Number of Cores Comprising the Virtual TMA 
To test whether T cell density depends on the number of cores used for quantification of each 
tumor area, we analyzed the relationship between mean T cell density of all patients by correlating 
the mean T cell densities of six cores with the mean T cell densities determined from one up to five 
cores quantified by virtual TMA. Here, increasing numbers of cores demonstrated positive, but 
variable correlations in each tumor region: tumoral CD3: 1 core, R = 0.34 vs. 6 cores, R = 0.35 (moderate 
T cell density score T cell density score
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correlation); marginal CD3: 1 core, R = 0.16 vs. 6 cores, R = 0.14 (weak correlation), respectively; 
tumoral CD8: 1 core, R = 0.41 vs. 6 cores (moderate correlation), R = 0.46; marginal CD8: 1 core, R = 
0.60 vs. 6 cores, R = 0.69 (strong correlation), respectively; however, determination of T cell density 
using six cores resulted in the highest correlation between quantification methods (versus 1–5 cores; 
Figure 4). 
 
Figure 4. Variance of correlations between T cell densities using analogue quantification and T cell 
densities using any possible combination of 1 to 6 virtual TMA cores to estimate the mean. Ascending 
numbers of cores resulted in a more precise approximation of correlation to the analogue values in 
each tumor area, except for marginal CD3 density. Top: Tumoral CD3: 1 core, R = 0.34 vs. 6 cores, R = 
0.35 (moderate correlation); marginal CD3: 1 core, R = 0.16 vs. 6 cores, R = 0.14 (weak correlation), 
respectively. Bottom: Tumoral CD8: 1 core, R = 0.41 vs. 6 cores, R = 0.46 (strong correlation); marginal 
CD8: 1 core, R = 0.60 vs. 6 cores, R = 0.69 (strong correlation), respectively; however, adding cores for 
quantification analysis led to a more precise approximation of the correlation between analogue and 
virtual TMA quantification. Note. R—Spearman's correlation coefficient. 
2.5. Approximation of T Cell Density between Quantification Methods Does Not Depend on the Specific T 
Cell Density of Each Core 
To test whether the approximation of T cell densities depends on the specific cores (or core 
location) used for quantification and hence would result from a systematic bias, we analyzed the 
cores sorted in ascending T cell densities (using the core with the lowest (1) to the highest (6) mean T 
Number of cores Number of cores
Number of cores Number of cores
RR
R R
CD8 - Central Tumor CD8 - Invasive Margin
CD3 - Central Tumor CD3 - Invasive Margin
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cell density) and compared them with the correlations between the mean T cell densities quantified 
by 6 cores versus mean T cell densities on full tissue sections. We show that using cores 2, 3 and 4 
(comprising medium to high T cell densities) results in the strongest correlation, demonstrating that 
the approximation of T cell densities is not related to the actual T cell density (and location) of each 
individual core, which makes a systematic bias unlikely (Figure 5). 
 
Figure 5. Correlation of the mean T cell densities of 6 cores with mean T cell densities of full tissue 
sections (dashed line) versus ascending sorted mean T cell densities of 1–6 cores. Strength of 
correlation between T cell densities on full tissue sections and virtual TMA does not depend on the 
mean T cell density of the cores chosen for correlation. From bottom to top: Tumoral CD3 – low T cell 
density core, R = 0.35 vs. high density core, Rs = 0.26 (moderate correlation), max. core 3, R = 0.40; 
marginal CD3 – low T cell density core, R = 0.18 vs. high density core, R = 0.17 (weak correlation), 
max. core 2, R = 0.19; tumoral CD8 – low T cell density core, R = 0.42 vs. high density core, R = 0.40 
(moderate correlation), max. core 2, R = 0.51; marginal CD8 - low T cell density core, R = 0.64 vs. high 
density core, R = 0.66 (strong correlation); max. core 4, R = 0.70. Note. R—Spearman's correlation 
coefficient. 
2.6. T Cell Density Varies Independently of the Number of Cores Chosen for Quantification by TMA 
We further wanted to evaluate how the number of cores chosen for averaging influences the 
variation in T cell density and how this methodological variation relates to the biological variation of 
all six cores. For this, the biological variation of all six cores was determined (boxplot) and the 
deviation to the ground truth of these six cores was calculated using all possible combinations of one 
to five cores for each parameter and each patient (histograms). We depicted these differences as 
distributions by ascending numbers of cores used for averaging parameters (one to five, grey 
histograms, respectively). Here, similar ranges of deviation of parameters were found compared to 
the respective biological variation of all six cores (boxplot), even when using all combinations of five 
cores of each patient. Grey bars show the percentages of averaged parameters inside the standard 
error (SE) of the six core values for each patient (Figure 6). However, the results of five averaged cores 
are not statistically different to the results from six cores, as (almost) all values (99.5%–100%) are 
Cores (sorted min > max)
R
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inside the standard error range; in fact, by using only four cores almost 20% of combinations are 
outside the SE range. 
 
Figure 6. Variations in T cell densities based on the number of cores chosen for quantification by 
virtual tissue microarray. Quantification of mean T cell densities using 5 cores for each patient (bar 
graph) shows a higher range of variation compared to mean T cell densities using 6 cores from all 
patients (boxplot). Top: Tumoral CD3 density: range 0–350 (boxplot); 1 core: 0–40 (SE = 28.1%) vs. 5 
cores: 0–150 (SE = 99.5%); marginal CD3 density: range 0–650 (boxplot); 1 core: 0–30 (SE = 27.9%) vs. 
5 cores 0–120 (SE = 100%). Bottom: Marginal CD8 density: range 0–100 (boxplot); 1 core: 0–120 (SE = 
27.2%) vs. 5 cores 0-200 (SE = 99.8%); tumoral CD8 density: range 0–200 (boxplot); 1 core: 0–100 (SE = 
26.4%) vs. 5 cores: 0-250 (SE = 100%). Note. Range - range of variation in T cell density; SE—standard 
error. 
2.7. Survival Analysis 
The median follow-up was 10.5 years (CI95 7.4–13.2) for all 75 patients, 12.6 years (CI95 10.5–14.9) 
for the group that received radiation therapy and 7.2 years (CI95 3.9–8.2) for the treatment-naïve 
group. During this time, 61 patients died; of these, 47 patients had received radiation therapy 
preoperatively and 13 patients had not. With regard to DFS, 20 patients relapsed after curative 
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With regard to OS, out of 75 patients comprising the entire cohort, 14 patients died after curative 
surgery; of these, 13 patients had received radiation therapy preoperatively and 1 patient had not. 
2.8. Analysis of Disease-Free and Overall Survival Based on T Cell Densities and Immune Checkpoint 
Protein Expression by Analogue Quantification on Full Tissue Sections 
Cox Regression analysis based on T cell densities and immune checkpoint protein expression on 
TILs quantified on full tissue sections was performed for DFS and OS. Here, CD3 density and PD-1 
expression in both tumor areas (CT, IM) showed a significant impact on both DFS and OS (CD3: CT, 
p = 0.018/IM, p = 0.002 and PD-1: CT, p = 0.037/IM, p = 0.016, respectively), whilst PD-L1 expression 
showed a trend towards improved survival (PD-L1: CT, p = 0.087/IM, p = 0.078); with regard to CD8 
density, only expression in the IM was associated with improved survival. Radiation therapy showed 
no impact, whilst patients with nodal positive RC had a 3.69 chance of relapse or death (p = 0.020). 
In a multiple Cox Regression model, nodal status remained as a crucial prognostic factor for DFS 
next to T cell density and immune checkpoint protein expression on TILs, whilst radiation therapy 
did not; however, CD3 density in the IM (p = 0.004) as well as PD-1 expression in the IM (p = 0.045) 
and the CT (p = 0.048) was shown to be an independent prognostic marker for DFS taking into account 
nodal status and preoperative radiation therapy as crucial factors influencing survival; CD8 density 
(p = 0.074) in the IM as well as PD-L1 expression in the IM and the CT (p = 0.067 and p = 0.050, 
respectively) showed a trend towards impaired DFS next to nodal status (Table 5). In a multiple Cox 
Regression model for OS, again nodal status remained a crucial prognostic factor next to T cell density 
or immune checkpoint protein expression on TILs, whilst radiation therapy did not; however, all 
factors tested are independent prognostic markers for OS (CD3: CT, p = 0.021/IM p = 0.002; CD8: CT, 
p = 0.029/IM, p = 0.029; PD-1: CT p = 0.037/IM p = 0.017) taking into account the nodal status and 
preoperative radiation therapy as crucial factors influencing survival; PD-L1 expression in the IM 
showed a trend towards influencing survival, whilst PD-L1 expression in the CT did not (Table 6). 
Table 5. Univariate (A) and multiple Cox Regression analysis (B) for disease-free survival of rectal 
cancer patients quantified using analogue quantification for T cell densities (full sections). 
Table A Univariate Analysis 
Factor HR CI95 p-value 
CD3 (CT) 0.45 0.23–0.88 0.018 
CD3 (IM) 0.33 0.16–0.65 0.002 
CD8 (CT) n.s. 
CD8 (IM) 0.48 0.23.1.00 0.049 
PD-1 (CT) 0.36 0.14–0.94 0.037 
PD-1 (IM) 0.30 0.11–0.79 0.016 
PD-L1 (CT) 0.51 0.24–1.10 0.087 
PD-L1 (IM) 0.42 0.16–1.10 0.078 
Radiation therapy (25 Gy) n.s. 
Nodal positive RC 3.69 1.23–11.08 0.020 
Table B  Multiple Model 
Factor HR CI95 p-value 
CD3 (CT)* n.s. 
Nodal positive RC 2.42 0.10–5.87 0.050 
CD3 (IM)* 0.46 0.27–0.79 0.004 
Nodal positive RC 2.49 1.03–6.05 0.043 
CD8 (CT)* n.s. 
Nodal positive RC 2.69 1.12–6.53 0.029 
CD8 (IM)* 0.59 0.33–1.05 0.074 
Nodal positive RC 2.78 1.14–6.74 0.024 
PD-1 (CT)* 0.45 0.20–0.99 0.048 
Nodal positive RC 2.45 1.01–5.94 0.047 
PD-1 (IM)* 0.48 0.23–0.98 0.045 
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Nodal positive RC 2.50 1.03–6.07 0.043 
PD-L1 (CT)* 0.54 0.28–1.04 0.067 
Nodal positive RC 2.13 0.87–5.21 0.099 
PD-L1 (IM)* 0.47 0.22–1.00 0.050 
Nodal positive RC 2.38 0.98–5.76 0.056 
Note. Table A – univariate analysis; Table B – multiple model: double lines indicate separate models; 
CT: central tumor, IM: invasive margin; RC: rectal cancer; HR: hazard ratio, CI: confidence interval; 
radiation therapy according to a hyper-fractionated short-term radiation protocol (preoperative 
administration of 2× 2.5 Gy/d during 5d: total dose of 25 Gy); PD-1 and PD-L1 expression was found 
on leucocytes; n.s.: not significant; *radiation therapy (25 Gy) was excluded from the model by the 
backward elimination procedure minimizing the Akaike information criterion (AIC); bold p-values—
statistical significance at the p < 0.05 level.  
Table 6. Univariate and multiple Cox Regression analysis for overall survival of rectal cancer patients 
quantified using analogue quantification for TC densities (full sections). 
Table A Univariate Analysis 
Factor HR CI95 p-value 
CD3 (CT) 0.45 0.23–0.88 0.018 
CD3 (IM) 0.33 0.16–0.65 0.002 
CD8 (CT) n.s. 
CD8 (IM) 0.48 0.23–1.00 0.049 
PD-1 (CT) 0.36 0.14–0.94 0.037 
PD-1 (IM) 0.30 0.11–0.79 0.016 
PD-L1 (CT) 0.51 0.24–1.10 0.087 
PD-L1 (IM) 0.42 0.16–1.10 0.078 
Radiation therapy (25 Gy) n.s. 
Nodal positive RC 3.69 1.23–11.08 0.020 
Table B  Multiple Models 
Factor HR CI95 p-value 
CD3 (CT)* 0.46 0.23–0.89 0.021 
Nodal positive RC 3.51 1.17–10.53 0.025 
CD3 (IM)* 0.35 0.18–0.69 0.002 
Nodal positive RC 3.44 1.14–10.33 0.028 
CD8 (CT)* 0.44 0.21–0.92 0.029 
Nodal positive RC 4.18 1.39–12.57 0.011 
CD8 (IM)* 0.44 0.21–0.92 0.029 
Nodal positive RC 4.18 1.39–12.57 0.011 
PD-1 (CT)* 0.35 0.13–0.94 0.037 
Nodal positive RC 3.62 1.21–10.87 0.022 
PD-1 (IM)* 0.30 0.11–0.81  0.017 
Nodal positive RC 3.60 1.20–10.86 0.023 
PD-L1 (CT) n.i. 
Nodal positive RC 4.26 1.41–12.86 0.010 
Radiation Therapy (25Gy) n.s. 
PD-L1 (IM)* 0.44 0.16–1.17 0.099 
Nodal positive RC 3.36 1.12–10.10 0.031 
Note. Table A – univariate analysis; Table B – multiple model: double lines indicate separate models; 
CT: central tumor, IM: invasive margin; RC: rectal cancer; HR: hazard ratio, CI: confidence interval; 
radiation therapy according to hyper-fractionated short-term radiation protocol (preoperative 
administration of 2× 2.5 Gy/d during 5d: total dose of 25 Gy); PD-1 and PD-L1 expression was found 
on leucocytes; n.s.: not significant; n.i.: not included/*radiation therapy (25 Gy) was excluded from 
the model by the backward elimination procedure minimizing the Akaike information criterion (AIC) 
; bold p-values – statistical significance at the p < 0.05 level. 
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2.9. Analysis of Disease-Free and Overall Survival Based on the Immunoscore Quantified on Virtual TMAs 
In contrast to the prognostic impact of T cell densities quantified on full tissue sections, the 
Immunoscore (2 cores in the CT, 2 cores in the IM) showed no impact on DFS or OS by univariate 
analysis and the multiple model (next to nodal status and preoperative radiation therapy) in this 
cohort of patients (Tables 7 and 8). 
Table 7. Univariate and multiple Cox Regression analysis for disease-free survival of rectal cancer 
patients using the Immunoscore (2 cores per tumor area, virtual TMA). 
Factor Univariate Analysis* Multiple Model* 
 HR CI95 p-value HR CI95 p-value 
Immunoscore n.s. n.s. 
Radiation therapy (25 Gy) n.s. n.s. 
Nodal positive RC n.s. n.s. 
Note. Radiation therapy according to a hyper-fractionated short-term radiation protocol 
(preoperative administration of 2× 2.5 Gy/d during 5d: total dose of 25 Gy); RC: rectal cancer; n.s.: not 
significant; n.i.: not included: excluded from the model by the backward elimination procedure 
minimizing the Akaike information criterion (AIC); *no differences were found in whether survival 
analysis was performed across all groups or compared between the radiation therapy group and the 
treatment-naïve group. 
Table 8. Univariate and multiple Cox Regression analysis for overall survival of rectal cancer patients 
using the Immunoscore (2 cores per tumor area, virtual TMA). 
Factor Univariate Analysis* Multiple Model* 
 HR CI95 p-value HR CI95 p-value 
Immunoscore n.s. n.i. 
Radiation therapy (25 Gy) n.s. n.i. 
Nodal positive RC n.s. n.s. 
Note. Radiation therapy according to a hyper-fractionated short-term radiation protocol 
(preoperative administration of 2× 2.5 Gy/d during 5d: total dose of 25 Gy); RC: rectal cancer; n.s.: not 
significant; n.i.: not included: excluded from the model by the backward elimination procedure 
minimizing the Akaike information criterion (AIC); *no differences were found in whether survival 
analysis was performed across all groups or compared between the radiation therapy group and the 
treatment-naïve group. 
2.10. Analysis of Disease-Free and Overall Survival Based on 6 Cores per Tumor Area Quantified on Virtual 
TMAs 
Here, tumoral CD3 density was the only factor with a trend towards an impact on DFS and with 
independent prognostic power for DFS (CD3: CT, p = 0.093 and p = 0.093, respectively). All other 
factors remained insignificant (Table 9). With regard to OS, tumoral CD3 density and nodal status 
showed a trend towards an impact on IS and an independent prognostic power for OS (CD3: CT, p = 
0.052 and p = 0.084, respectively); in addition, nodal status as a factor in the multiple model tended 
to remain an independent prognostic marker of OS next to T cell density and preoperative radiation 
therapy (nodal status, p = 0.074; Table 10). 
Table 9. Univariate and multiple Cox Regression analysis for disease-free survival of rectal cancer 
patients (6 cores per tumor region, virtual TMA). 
Table A Univariate Analysis 
Factor HR CI95 p-value 
CD3 (CT) 0.38 0.10–1.20 0.093 
CD3 (IM) n.s. 
CD8 (CT) n.s. 
CD8 (IM) n.s. 
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Radiation therapy (25 Gy) n.s. 
Nodal positive RC n.s. 
Table B  Multiple Model 
Factor HR CI95 p-value 
CD3 (CT)* 0.34 0.10-1.20 0.093 
Nodal positive RC n.i. 
CD3 (IM)* n.i. 
Nodal positive RC n.s. 
CD8 (CT)* n.i. 
Nodal positive RC n.s. 
CD8 (IM)* n.i. 
Nodal positive RC n.s. 
Note. Table A – univariate analysis; Table B – multiple model: double lines indicate separate models; 
CT: central tumor, IM: invasive margin; HR: hazard ratio, CI: confidence interval; radiation therapy 
according to a hyper-fractionated short-term radiation protocol (preoperative administration of 2× 2.5 
Gy/d during 5d: total dose of 25 Gy); RC: rectal cancer; n.s.: not significant; n.i.: not 
included/*radiation therapy (25 Gy) was excluded from the model by the backward elimination 
procedure minimizing the Akaike information criterion (AIC); trend towards statistical significance 
at the p < 0.1 level. 
Table 10. Univariate and multiple Cox Regression analysis for overall survival of rectal cancer 
patients (6 cores per tumor region, virtual TMA). 
Table A Univariate Analysis 
Factor HR CI95 p-value 
CD3 (CT) 0.20 0.04-1.01 0.052 
CD3 (IM) n.s. 
CD8 (CT) n.s. 
CD8 (IM) n.s. 
Radiation therapy (25 Gy) n.s. 
Nodal positive RC 2.88 0.90–9.20 0.074 
Table B  Multiple Model 
Factor HR CI95 p-value 
CD3 (CT)* 0.23 0.04–1.22 0.084 
Nodal positive RC n.s. 
CD3 (IM)* n.i. 
Nodal positive RC 2.88 0.90–9.20 0.074 
CD8 (CT)* n.i. 
Nodal positive RC 2.88 0.90–9.20 0.074 
CD8 (IM)* n.i. 
Nodal positive RC 2.88 0.90–9.20 0.074 
Note. Table A – univariate analysis; Table B – multiple model: double lines indicate separate models; 
CT: central tumor, IM: invasive margin; HR: hazard ratio, CI: confidence interval; radiation therapy 
according to a hyper-fractionated short-term radiation protocol (preoperative administration of 2× 2.5 
Gy/d during 5d: total dose of 25 Gy); RC: rectal cancer; n.s.: not significant; n.i.: not 
included/*radiation therapy (25 Gy) was excluded from the model by the backward elimination 
procedure minimizing the Akaike information criterion (AIC); trend towards statistical significance 
at the p < 0.1 level.  
3. Discussion 
The impact of the tumor immune contexture on the prognosis of CRC patients is not doubted 
and the consensus Immunoscore is internationally validated for implementation of a “TNM-Immune 
classification” of cancer [31]. However, concerns have been raised regarding the methodology used 
for immune marker quantification using TMA in particular [20–25,32]. 
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In this study, we primarily aimed to explore the impact of a hyperfractionated short-term 
preoperative radiation protocol on immunomodulation; hereby, we have been confronted with the 
issue of spatial tumor heterogeneity, which led us to investigate different methods of quantifying 
immune cells on virtual TMA versus full tissue sections in a structured approach. We found that 
hyperfractionated short-term preoperative radiation therapy resulted in a decrease in immune cell 
infiltration and that the tissue area represents a crucial factor in assessing immune markers: If 
quantified on full tissue sections, CD3 positive, CD8 positive T cells and PD-1 positive TILs had a 
significant impact and represent independent prognostic factors for DFS and OS, whilst survival 
analysis based on virtual TMA remained insignificant. 
Irradiation promotes pro-immunogenic effects, that depend on dose, fractionation and 
sequencing. Recent studies report that irradiation doses in low ranges promote an innate and 
adaptive immune response that supports building anti-tumor immunity [14,33,34]. We here 
evaluated tumor immune infiltration after treatment with a hyperfractionated short-term radiation 
protocol, that involves a lower dose than usual (cumulative dose 25 Gy: 2× 2.5 Gy over 5 days), which 
still resulted in an overall decrease of immune marker expression (T cells, immune checkpoint 
proteins) compared to treatment-naïve RC samples. The infiltration of stromal CD8 positive T cells 
has been demonstrated to double in samples of RC patients treated with preoperative 
chemoradiotherapy (cumulative dose 20 Gy: 1× 4 Gy over 7 days with concomitant administration of 
tegafur/uracil) [35]. Another study using the same methodology, investigated T cell infiltration and 
immune checkpoint protein expression after extensive chemoradiation (cumulative dose 40–45 Gy: 
25-28 fractions over 5 weeks with concomitant fluoropyrimidine-based chemotherapy) and found an 
increase in CD8 positive T cells and only very low PD-L1 protein expression on stromal cells; similar 
to our study, CD8 positive T cells were associated with a favorable outcome [16]. In both studies, T 
cell infiltration and immune checkpoint protein expression was quantified analoguously comparing 
pretreatment biopsies and posttreatment resected full tissue sections. 
With regard to immune checkpoint proteins, quantification is challenging due to weak staining 
intensity depending on the antibody used [22,28]. Accordingly, recent reports investigating different 
treatment protocols showed conflicting data on post-treatment immune checkpoint protein 
expression in RC [36–39]; of note, a meta-analysis demonstrated general agreement on the association 
of PD-L1 protein expression with poor prognosis and on its applicability as a biomarker in CRC 
patients [40]. Our data, based on full section analysis, support the fact that patients with advanced 
RC (Dukes stage D) demonstrate lower infiltration of PD-L1 positive TILs both in the CT and the IM. 
In addition, we found that expression of PD-1 positive TILs (and tendentially PD-L1) in the CT and 
the IM was associated with poor prognosis and proved as an independent prognostic factor for DFS 
and OS. These findings might be explained by tumor immune evasion that results from T cell anergy 
upon interaction of the inhibitory immune checkpoint protein PD-1 with PD-L1 expressed on tumor 
cells or antigen-presenting cells. 
Upon quantification of full sections for immune marker expression, we encountered the issue of 
spatial tumor heterogeneity that is well described in cancer tissue [20–26]. Heterogeneous clustering 
of CD3 and CD8 positive T cells, as well as PD-1 and PD-L1 positive TILs was evident; however, 
evaluation by board-certified pathologists ensured that these heterogeneous expression patterns 
were seen in the context of the entire tumor section, whilst digital quantification on selected tissue 
cores would not have allowed any conclusions to be drawn regarding the spatial structure of the 
tumor. Consistently, the irradiation-induced immune ablation we found here is controversial to the 
reports using biopsies for quantification [16,35]. Hence, TMA-based marker analysis might result in 
incorrect cut-off definitions for tools like the Immunoscore on which prognostic decisions are based 
on [18,27]. Still TMAs are used routinely as they offer cost effective analysis of large patient cohorts. 
However, since this is an outstanding case that conflicts the above-mentioned data on 
immunomodulation after (chemo)radiotherapy, we focused on reconstruction of the initial scenario 
by virtually establishing TMA cores for digital quantification. We found that T cell densities 
correlated using both quantification methods; lower correlations in CD3 densities might be ascribed 
to the lower staining intensity of the antibody used. However, a trained and validated algorithm was 
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used for digital analysis and each slide was manually corrected by a trained observer. We therefore 
decided to expand virtual TMA core establishment to evaluate whether the tissue area (represented 
by the number of cores) used for quantification influenced the approximation of T cell density. As 
previously described, expanding the area for quantification using bigger cores in the case of a TMA 
or upgrading to full section analysis minimizes the chance of measuring heterogeneous marker 
patterns [22,24,28]. Hence, correlations between analogue and digital estimations were improved by 
increasing the number of TMA cores used for quantification of T cell densities, independent of the 
mean T cell count of the core (and hence location) chosen for quantification. In fact, T cell density 
varied largely between the TMA cores, which once more might be attributable to spatial tumor 
heterogeneity. 
These findings were reflected in the survival analysis conducted using immune cell marker 
density quantified on full tissue sections versus virtual TMAs. Similar to recent reports, survival 
analysis based on full section quantification demonstrated a significant prognostic impact for high 
CD3 and CD8 positive T cell (as well as PD-1 positive TIL) densities in the CT and the IM on DFS as 
well as OS. Neither survival analysis based on virtual TMA nor the Immunoscore showed prognostic 
significance, when analyzed using two cores for each tumor area (CT, IM) as previously described in 
RC patients [18]. Since the Immunoscore has recently been internationally validated and the impact 
of tumor immune cell infiltration on prognosis of CRC patients is not doubted [31], we attribute the 
insignificant results to the small number of patients (n = 75) comprising this study cohort. 
In addition to the small sample size, another limitation of this study is that the area of most RC 
samples was relatively small and therefore virtual TMA establishment for digital quantification was 
limited to 6 cores per tumor area. However, we demonstrate here that 6 cores per tumor area 
represent comparable T cell densities as those quantified on full tissue sections and an extension of 
the area for digital evaluation by virtual TMA would therefore have been redundant. 
4. Materials and Methods 
4.1. Study Cohort 
A total of 75 patients with RC that were subsequently operated on between 2000 and 2009 at the 
Medical University of Vienna were selected and retrospectively analyzed. Out of these, 60 patients 
had locally advanced RC and were treated after a hyper-fractionated short-term pre-operative 
radiation therapy protocol [30]. Within this protocol, patients received 2× 2.5 Gy applied twice daily 
over 5 days (Monday to Friday) to a total dose of 25 Gy. Surgery was performed the week thereafter. 
Partial and total mesorectal excision with a stapled anastomosis for tumors located in the upper third 
and the middle and lower rectum was performed, respectively. Protective ileostomies were added at 
the surgeon’s discretion. Another 15 treatment-naïve human RC samples were collected as a control 
population. Each sample was selected by a board-certified pathologist. Patient data were handled 
according to Good Scientific Practice (GSP) Guidelines. Radiographic data were analyzed according 
to the response evaluation criteria in solid tumors (RECIST). The study was approved by the ethics 
committee of the Medical University of Vienna (EK #1197/2019). 
4.2. Immunohistochemistry (IHC) 
IHC was conducted on 1 µm thick full tissue sections and stained with markers for tumor-
infiltrating lymphocytes (TILs; CD3, CD8) and immune checkpoint proteins (PD-1, PD-L1). Staining 
was performed using a Leica Bond RX Automated Stainer (Leica Products/Equipment, Leica 
Microsystems, Inc., Buffalo Groove, IL). Slides with incubated for 30 minutes at 95°C, followed by 
dewaxing with Leica Bond Dewax solution (Leica Biosystems, Inc., Buffalo Groove, IL; Cat no. 
AR9222), antigen retrieval with Bond Epitope Retrieval 1 solution (Leica Biosystems, Inc., Buffalo 
Groove, IL; Cat no. AR9961) and blocking of unspecific binding sites with 2% goat serum. Primary 
antibody binding was visualized with diaminobenzidine chromogen and a hematoxylin counterstain, 
using the Leica Bond Refine Detection kit (Leica Biosystems, Inc., Buffalo Groove, IL; Cat no. DS9800). 
Primary antibodies were diluted in Leica Bond Antibody Diluent buffer (Leica Biosystems, Inc., 
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Buffalo Groove, IL; Cat no. AR9352) as follows: anti-CD3 (Abcam, Cambridge, MA, USA; Cat no. 
ab5690; rabbit polyclonal) 1:300, anti-CD8 (Abcam, Cambridge, MA, USA; Cat no. ab4055; rabbit 
polyclonal) 1:300), anti-PD-1 (Abcam, Cambridge, MA, USA; Cat no. ab137132; rabbit polyclonal) 
1:75, anti-PD-L1 (Abcam, Cambridge, MA, USA; Cat no. ab205921; rabbit polyclonal) 1:100). 
4.3. Analogue Quantification of T Cell Density and Immune Checkpoint Protein Expression 
Analogue quantification of protein expression (CD3, CD8, PD-1, PD-L1) in the central tumor 
(CT) and in the invasive margin (IM) was performed by two independent trained investigators in a 
double-blinded manner. T cell density was defined as no (0), low (1), moderate (2) or high (3) with 
respect to positive T cells or TILs present. When different results were determined by the 2 
independent investigators, samples were re-evaluated together and an agreed final score was 
determined. 
4.4. Virtual Tissue Microarray Establishment 
For comparison of quantitative marker expression, full tissue sections were scanned and images 
were acquired with an Axio Imager Z2 microscope, using a PixeLINK PL-D674 CU Camera and a 20x 
objective (with a 0.5 Aperture). Virtual TMA was established by randomly selecting two virtual cores 
each in the CT and IM using StrataQuestTM® (TissueGnostics, Vienna, Austria). Digital analysis was 
performed on the acquired images. The Color Separation engine was used on the original BF RGB 
images to generate two grey scale images for the blue hematoxylin marker and the brown T cell 
marker. The blue shade image was used for automatic cell detection. Measurements (for CD3 and 
CD8 positive T cells) were generated using the Global Standard Measurements engine. Finally, 
manual correction was performed to correct automatic cell detection as well as to determine whether 
the manual marker assessment was positive or negative. Statistics were generated automatically 
based on total event count, total valid marker count, count and mean intensity of brown-positive cells 
as well as count and mean intensity of brown-negative cells; results were then corrected for manually-
validated positive or negative cells. The process of digital analysis, from automated cell detection via 
marker assessment and manual correction to the final results of positive and negative T cells is shown 
in Supplementary Figure S2. 
4.5. Immunoscore Calculation 
TMA core sizes (CT - 0.6 mm diameter; IM - 1 mm diameter) and the cut-off values for T cell 
density for Immunoscore calculation in RC were chosen as previously proposed [18]. In short, each 
tumor was categorized into high or low density for CD3 and CD8 expression (n = cells/mm2) in each 
tumor area according to cut-off values predetermined using the minimum p value approach (CD3 
CT, 256 cells/mm2; CD3 IM, 144 cells/mm2; CD8 CT, 202 cells/mm2; CD8 IM, 50 cells/mm2). Patient 
stratification was performed according to a ‘four-category score’ based on the respective cut-offs (i.e., 
0-4) or a ‘dichotomized score’ based on the 0–4 score, i.e., 0 versus 1–4. 
4.6. Estimation of Approximation of T Cell Density Quantified by Regions of Interest vs. Full Tissue Sections 
In order to estimate the tissue area needed to approximate the T cell densities quantified on 
virtual TMA to the T cell densities on full sections, another 4 additional cores were randomly added 
to each area (CT, IM). Hence, a total of 6 cores per area were analyzed, which represented the 
maximum possible due to the size of tumor tissue available. Digital quantification was performed for 
CD3 and CD8 T cell densities as described above. 
4.7. Statistical Analysis 
Statistical analyses were performed in R v3.6.0 (The R Foundation for Statistical Computing, 
Vienna, Austria [41]. Kaplan Meier estimates and Cox regressions for overall survival were 
conducted with the functions survfit and coxph of the R-package survival v2.44–1.1 [42]. Final Cox 
models were selected by the backward selection method minimizing the Akaike Information 
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Criterion (AIC) with function stepAIC of R-package MASS v7.3–51.4 [43] Correlations between 
analogue whole slide and digitally determined core marker expression values were calculated with 
the Spearman's rank correlation coefficient method. Differences in marker expression values between 
the groups were estimated using the non-parametric Kruskal Wallis test. 
5. Conclusions 
We conclude that the tissue area used for immune marker quantification represents a crucial 
factor for the evaluation of prognostic biomarker potential. An option to avoid the above-mentioned 
pitfalls was presented in a recent study that demonstrated an optimized digital method using whole 
slide imaging for investigation of the spatial quantitative expression of immune cells in CRC samples 
by virtual microscopy [32,44]. The international validation of the Immunoscore was based on a 
respective image-analysis system with digital pathology software [31]. By using such methods, it can 
be assumed that quantification bias is kept to a minimum [45,46]; at the same time, digital processing 
is effective and tissue-saving. 
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